London
· Delayed Price · Currency is GBP · Price in GBXCeladon Pharmaceuticals Statistics
Total Valuation
Celadon Pharmaceuticals has a market cap or net worth of GBP 10.67 million. The enterprise value is 15.46 million.
| Market Cap | 10.67M |
| Enterprise Value | 15.46M |
Important Dates
The next estimated earnings date is Friday, December 27, 2024.
| Earnings Date | Dec 27, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Celadon Pharmaceuticals has 68.85 million shares outstanding. The number of shares has increased by 2.69% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 68.85M |
| Shares Change (YoY) | +2.69% |
| Shares Change (QoQ) | +4.03% |
| Owned by Insiders (%) | 53.48% |
| Owned by Institutions (%) | 18.82% |
| Float | 30.61M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 75.57 |
| PB Ratio | 4.12 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -2.95 |
| EV / Sales | 118.90 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -2.69 |
Financial Position
The company has a current ratio of 1.92, with a Debt / Equity ratio of 1.95.
| Current Ratio | 1.92 |
| Quick Ratio | 1.00 |
| Debt / Equity | 1.95 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.83 |
| Interest Coverage | -8.36 |
Financial Efficiency
Return on equity (ROE) is -190.71% and return on invested capital (ROIC) is -41.33%.
| Return on Equity (ROE) | -190.71% |
| Return on Assets (ROA) | -34.40% |
| Return on Capital (ROIC) | -41.33% |
| Revenue Per Employee | 4,815 |
| Profits Per Employee | -193,778 |
| Employee Count | 27 |
| Asset Turnover | 0.01 |
| Inventory Turnover | 0.39 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -84.05% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -84.05% |
| 50-Day Moving Average | 29.84 |
| 200-Day Moving Average | 67.77 |
| Relative Strength Index (RSI) | 21.20 |
| Average Volume (20 Days) | 73,595 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Celadon Pharmaceuticals had revenue of GBP 130,000 and -5.23 million in losses. Loss per share was -0.08.
| Revenue | 130,000 |
| Gross Profit | 39,000 |
| Operating Income | -4.93M |
| Pretax Income | -5.49M |
| Net Income | -5.23M |
| EBITDA | -4.55M |
| EBIT | -4.93M |
| Loss Per Share | -0.08 |
Balance Sheet
The company has 16,000 in cash and 4.78 million in debt, giving a net cash position of -4.76 million or -0.07 per share.
| Cash & Cash Equivalents | 16,000 |
| Total Debt | 4.78M |
| Net Cash | -4.76M |
| Net Cash Per Share | -0.07 |
| Equity (Book Value) | 2.45M |
| Book Value Per Share | 0.04 |
| Working Capital | 808,000 |
Cash Flow
In the last 12 months, operating cash flow was -5.55 million and capital expenditures -192,000, giving a free cash flow of -5.74 million.
| Operating Cash Flow | -5.55M |
| Capital Expenditures | -192,000 |
| Free Cash Flow | -5.74M |
| FCF Per Share | -0.08 |
Margins
| Gross Margin | 30.00% |
| Operating Margin | -3,793.85% |
| Pretax Margin | -4,225.38% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -4,418.46% |
Dividends & Yields
Celadon Pharmaceuticals does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.69% |
| Shareholder Yield | -2.69% |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Celadon Pharmaceuticals has an Altman Z-Score of -0.27. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.27 |
| Piotroski F-Score | n/a |